ameltia

Medicine got smarter.

Delivery didn't.

Reimagining how therapeutics reach the body.

See what's next ↓

First, we swallowed medicine.

But the stomach acids got in the way.

So then, we injected medicine.

Solving one problem by creating new ones:

liquids. stabilisers. cold chains. systemic exposure.

What if the next revolution isn't a better drug?

What if it's a better way in?

Treatments should fit into people's lives.

Being sick is already a burden, getting better shouldn't be.

And here's the thing.

Pharma wants this too.

Better delivery isn't just better for patients.

Less pain

Less burden

More autonomy

Better treatment outcomes

It's better business.

Differentiation

Adherence

Lifecycle extension

New IP

New markets

ameltia reimagines how medicines are administered, working across indication families.

GLP-1 agonists

Monoclonal antibodies

CGRP antagonists

Hyaluronic acid

Peptide hormones

mRNA vaccines

Botulinum toxins

Growth factors

Corticosteroids

We're starting through the skin, and attacking migraine first.

Curious how? Get in touch

ameltia

is delivering the next generation of therapeutics. Better efficacy. Better adherence. Better outcomes. Starting with the skin. Starting with migraine.

A revolution designed for patients, desired by pharma.

Who's behind this revolution?

Bioengineer meets pharma strategist meets foresight officer.

Led by Dr Beatrice Baumberger Altirriba, a team obsessed with making medicine human-centered. And smart enough to know pharma has to win too.

People who've built in labs, navigated pharma corridors, and think 100 years forward. People who know that delivery is not a constraint: it's the opportunity.

Medicine got smarter.

Now the delivery needs to catch up.

ameltia

Reimagining how medicines reach the body.

Get in touch →

We're just getting started.